Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn't Discovered Yet
10:28am, Friday, 28'th Jun 2024
Searching for quality undiscovered biotech stocks can be a bit like a treasure hunt. The biotech scene is full of intriguing innovators trying to progress their treatments through various clinical tri
3 AI Stocks on the Edge of a Massive Surge
08:15am, Thursday, 27'th Jun 2024
Last week, Nvidia (NASDAQ: NVDA ) briefly eclipsed Microsoft (NASDAQ: MSFT ) as the world's most valuable company. The AI chip maker is now worth $3.
Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
10:07pm, Wednesday, 26'th Jun 2024
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug disc
Recursion Announces Proposed Offering of Class A Common Stock
04:06pm, Wednesday, 26'th Jun 2024
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug disc
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
06:55pm, Tuesday, 25'th Jun 2024
Recursion Pharmaceuticals (RXRX) reachead $9.38 at the closing of the latest trading day, reflecting a +0.43% change compared to its last close.
Recursion CEO Chris Gibson talks integrating AI into drug development process
06:18pm, Monday, 24'th Jun 2024
Chris Gibson, Recursion Pharmaceuticals CEO, joins 'Closing Bell Overtime' to talk its partnership with Nvidia, its investors day, drug discovery and more.
Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data
09:00am, Monday, 24'th Jun 2024
SAN MATEO, Calif.--(BUSINESS WIRE)--Helix, a leading population genomics company and provider of precision medicine genomics solutions, today announced a groundbreaking multi-year agreement with Recur
Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day
08:00am, Monday, 24'th Jun 2024
SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will give updated pipeline guidan
Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery
03:36am, Monday, 24'th Jun 2024
This thesis makes the case for an investment in Recursion Pharmaceuticals operating as a TechBio which "industrializes" the process of drug discovery in contrast to a typical biotech. The difference b
Recursion Pharmaceuticals: Unprecedented Scale
10:53am, Monday, 17'th Jun 2024
Recursion Pharmaceuticals is an AI-enabled drug discovery company, differentiated by its scale and focus on understanding biology. The company has a broad pipeline across various therapeutic areas and
3 Stocks Under $10 Set to Quadruple by 2025: June Edition
02:40pm, Thursday, 13'th Jun 2024
Low-priced stocks under $10 can be explosively awarding. That is, if you spot the right one at the right time with the right catalyst.
Nvidia Owns These 4 Stocks. Here's How They're Doing.
11:37am, Saturday, 08'th Jun 2024
Nvidia has been one of the best-performing stocks on Wall Street since 2023, amassing holdings in four companies along the way.
Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim
09:00am, Friday, 07'th Jun 2024
Recursion hopes to transform the healthcare industry with its innovative drug discovery platform. The small company has gained the interest of Nvidia, which has invested in the business.
Nvidia's Golden Handshake: 3 Stocks Reaping the Rewards of an NVDA Alliance
06:26am, Wednesday, 05'th Jun 2024
The AI craze may be slowing, but that doesn't mean there's not plenty of opportunity available. While investing heavily in Nvidia (NASDAQ: NVDA ) could keep the cash coming in (considering its recent
1 Disruptive Biotech Stock to Buy Now, and 1 to Consider
10:15am, Monday, 03'rd Jun 2024
Biotechs that aspire to be disruptive are quite risky. However, they do offer the chance of disproportionate rewards.
